Does TAFASITAMAB Cause Off label use? 203 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 203 reports of Off label use have been filed in association with TAFASITAMAB (MONJUVI). This represents 14.6% of all adverse event reports for TAFASITAMAB.
203
Reports of Off label use with TAFASITAMAB
14.6%
of all TAFASITAMAB reports
43
Deaths
73
Hospitalizations
How Dangerous Is Off label use From TAFASITAMAB?
Of the 203 reports, 43 (21.2%) resulted in death, 73 (36.0%) required hospitalization, and 22 (10.8%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAFASITAMAB. However, 203 reports have been filed with the FAERS database.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
Thrombocytopenia (60)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which TAFASITAMAB Alternatives Have Lower Off label use Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR